Event dossier

RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves

Hims may have a chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.

1 report1 sourceApr 16, 2026, 8:19 PM
FilterCNBC
Clustered coverageCNBC
Coverage timeline1
Coverage timeline

Coverage timeline

Ranked reports inside the event cluster. Open any publisher link to read the original coverage.

CNBCApr 16, 2026, 8:19 PM

RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves

Hims may have a chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.

Related events

Related events

Nearby clusters pulled from title, summary, and keyword similarity in PostgreSQL.